Peptide Comparison
BPC-157 vs TB-500
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Use together
Both are popular for tendon and ligament recovery; both have essentially zero human RCT data. BPC-157's evidence is rodent-heavy and concentrated in one Croatian research group; TB-500 has thymosin-beta-4 fragment biology with broader independent corroboration. They're commonly stacked because the proposed mechanisms are orthogonal. Pick BPC-157 for GI/wound healing, pick TB-500 for systemic actin-regulation and cardiac/cell-migration support, or stack them (the GLOW/KLOW or Recovery Base protocols) if you're already going off-label.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
The actual difference
BPC-157 promotes angiogenesis via VEGFR2 and stabilizes the gut barrier. TB-500 binds and sequesters G-actin to regulate cytoskeletal dynamics and cell migration. Different molecular targets; partial overlap on the angiogenesis and tissue-repair endpoints. Both are listed as 'Compounding Restricted' in our catalog and neither has a published Phase 2/3 human trial.
Which one to pick
Pick BPC-157 if
- GI mucosal repair is the goal (BPC-157's origin story is a fragment of human gastric juice protein)
- Tendon/ligament work where the bulk of forum reports concentrate
- Oral dosing is on the table (acetate form has limited oral data)
Pick TB-500 if
- Systemic injury or cardiac/cell-migration applications
- You want the better-replicated mechanism story (independent labs have studied thymosin beta-4)
- Less-frequent dosing (twice-weekly load vs daily)
Avoid both if
- Personal or family cancer history (theoretical pro-angiogenic and proliferation concerns; never resolved in humans)
- Pregnant or planning pregnancy
- You require FDA-approved tendon healing - neither qualifies
Used together in
- GLOW / KLOW: Tissue repair, anti-inflammation, skin regeneration
- Recovery Base: Muscle, tendon, ligament healing
Common confusions
- 'BPC-157 has been proven in human trials'. False. There's no published Phase 2/3 human RCT. Forum claims of efficacy are anecdote, not evidence.
- 'BPC-157 and TB-500 work the same way'. False. They share an angiogenesis story but the molecular mechanisms (VEGFR2 vs actin sequestration) are distinct.
- 'Compounded BPC-157 from a US pharmacy is legal'. Almost always false. The FDA placed BPC-157 on the 503A Category 2 bulk substances list in 2023; compounding pharmacies cannot legally use it for human prescriptions in the US.
Side-by-side
| BPC-157 | TB-500 | |
|---|---|---|
| Class | Synthetic pentadecapeptide; cytoprotective | Thymosin β4 fragment; tissue repair |
| Drug class | Tissue Repair | Tissue Repair |
| Mechanism | Promotes angiogenesis via VEGFR2 [1]; upregulates growth factors [1]; modulates NO and dopamine pathways [1]; stabilizes gut barrier [1] | Binds and sequesters G-actin; promotes actin polymerization; upregulates angiogenesis and cell migration |
| Route | SC / IM / Oral / Intranasal | SC / IM |
| Half-life | less than 30 min (IV and IM in rats and dogs; oral not measured) | Several hrs to days (tissue uptake) |
| Dosage (research) | 250 mcg SC 2x daily near injury (Seeds Vol 1 starting dose, common upper bound 500 mcg per dose); 250 mcg oral 2x daily | 2-2.5 mg SC/IM 2x weekly for 4-6 week load; then 2 mg monthly |
| Evidence tier | Anecdotal + Animal Studies | Anecdotal + Animal Studies |
| Research depth | 174 indexed | 76 indexed |
| Availability | Compounding Restricted | Compounding Restricted |
| Reported risks | Limited human trials [1]; injection site irritation; theoretical pro-angiogenic/tumor concerns [1] | WADA-banned; limited human data; injection site pain; lethargy; theoretical proliferation concerns |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick BPC-157 or TB-500?
Both are popular for tendon and ligament recovery; both have essentially zero human RCT data. BPC-157's evidence is rodent-heavy and concentrated in one Croatian research group; TB-500 has thymosin-beta-4 fragment biology with broader independent corroboration. They're commonly stacked because the proposed mechanisms are orthogonal. Pick BPC-157 for GI/wound healing, pick TB-500 for systemic actin-regulation and cardiac/cell-migration support, or stack them (the GLOW/KLOW or Recovery Base protocols) if you're already going off-label.
What is the difference between BPC-157 and TB-500?
BPC-157 is classed as Synthetic pentadecapeptide; cytoprotective; TB-500 is classed as Thymosin β4 fragment; tissue repair. Reported mechanism: BPC-157, Promotes angiogenesis via VEGFR2; upregulates growth factors; modulates NO and dopamine pathways; stabilizes gut barrier; TB-500, Binds and sequesters G-actin; promotes actin polymerization; upregulates angiogenesis and cell migration. Reported half-life: BPC-157, less than 30 min (IV and IM in rats and dogs; oral not measured); TB-500, Several hrs to days (tissue uptake). Routes in published studies: BPC-157, SC / IM / Oral / Intranasal; TB-500, SC / IM.
Which has stronger evidence, BPC-157 or TB-500?
BPC-157 and TB-500 sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. BPC-157 is graded Anecdotal + Animal Studies, with 9 cited sources on its reference page and 174 indexed studies. TB-500 is graded Anecdotal + Animal Studies, with 2 cited sources on its reference page and 76 indexed studies.
Which is more accessible, BPC-157 or TB-500?
Neither BPC-157 nor TB-500 is an FDA-approved drug. Catalog status: BPC-157, Compounding Restricted; TB-500, Compounding Restricted. FDA's Pharmacy Compounding Advisory Committee voted 8 for, 6 against, 1 abstention on 23 July 2026 to recommend BPC-157 for the 503A Bulks List; the vote is advisory and changes nothing by itself. FDA's Pharmacy Compounding Advisory Committee voted 8 for, 6 against, 1 abstention on 23 July 2026 to recommend TB-500 for the 503A Bulks List; the vote is advisory and changes nothing by itself.
Are BPC-157 and TB-500 ever combined?
Yes. GLOW / KLOW, Recovery Base are documented stacks containing both BPC-157 and TB-500; the stack page gives the stated rationale.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…